- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT06206408
페졸리네탄트가 폐경기를 겪고 있는 일본 여성의 안면홍조 감소에 도움이 되는지 확인하기 위한 연구 (Starlight 2)
폐경과 관련된 혈관 운동 증상(일과성 열감)을 겪고 있는 일본 여성을 대상으로 Fezolinetant의 효능과 안전성을 평가하기 위한 제3상, 무작위, 위약 대조, 이중 맹검 연구
Hot flashes are the most common reason women going through menopause seek medical attention. Hormone replacement therapy, or HRT, is most often prescribed to treat hot flashes. However, HRT can't be used by all women or for as long as may be needed.
Researchers want to find other ways to treat hot flashes. Fezolinetant is a medicine to treat hot flashes in women going through menopause. Fezolinetant is an approved medicine in the US. Further studies are needed before it is available in other regions such as Asia.
This study will confirm if fezolintant helps reduce the number of hot flashes in Japanese women going through menopause.
Women that want to take part in the study will be given an electronic handheld device with an app to track their hot flashes. Some women may be able to use the app on their own smartphone. Before the women are assigned a treatment, they will record information about their hot flashes.
Women will either take a lower or higher dose of fezolinetant, or a placebo. This is decided by chance alone. The placebo looks like fezolinetant but will not have any medicine in it.
The women will take 2 tablets of the study medicine (lower or higher dose of fezolinetant, or the placebo) once a day for up to 12 weeks. They will either take 1 tablet of fezolinetant (higher or lower dose) and 1 placebo tablet, or they will take 2 placebo tablets. The women will continue to record information about their hot flashes on the electronic device or their smartphone.
During the study, the women will visit the study clinic a few times. At each visit they will be asked if they had any medical problems and will use an electronic device at the clinic to answer questions about how the hot flashes affect their daily life. Other checks will include a medical examination, vital signs (temperature, blood pressure and pulse). Some blood and urine samples will be taken for laboratory tests. At some visits, the women will also have an ECG to check their heart rhythm. Women who have a womb (uterus) will also have a test called a transvaginal ultrasound. A probe is gently placed inside the vagina. Sound waves will create a picture of the organs in the pelvis. This will allow the study doctor to look more closely at the uterus and surrounding organs.
The last clinic visit will be 3 weeks after the women take their final tablets of the study medicine (1 tablet of lower or higher dose of fezolinetant and 1 placebo tablet, or 2 placebo tablets).
연구 개요
연구 유형
등록 (실제)
단계
- 3단계
연락처 및 위치
연구 장소
-
-
-
Sapporo, 일본
- NISHIKAWA Women's Health Clinic
-
-
Aichi-ken
-
Chita-gun, Aichi-ken, 일본
- Chita Kosei Hospital
-
Kōnan, Aichi-ken, 일본
- Konan Kosei Hospital
-
Nagoya, Aichi-ken, 일본
- Daido Clinic
-
Nagoya, Aichi-ken, 일본
- MEITETSU Hospital
-
Toyota-shi, Aichi-ken, 일본
- Toyota Kosei Hospital
-
-
Chiba
-
Chiba, Chiba, 일본
- Chiba Aoba Municipal Hospital
-
Funabashi-shi, Chiba, 일본
- Aiiku Ladies Clinic
-
Kashiwa-shi, Chiba, 일본
- Tsujinaka Hospital Kashiwanoha
-
Matsudo-shi, Chiba, 일본
- Juno Vesta Clinic hatta
-
-
Fukuoka
-
Fukuoka, Fukuoka, 일본
- Fukuoka Mirai Hospital
-
Fukuoka, Fukuoka, 일본
- Mori Ladies Clinic
-
-
Fukushima
-
Fukushima, Fukushima, 일본
- Nishiguchi Clinic Fujinka
-
-
Gunma
-
Takasaki-shi, Gunma, 일본
- National Hospital Organization Takasaki General Medical Center
-
Takasaki-shi, Gunma, 일본
- Sato Hospital
-
-
Hiroshima
-
Hiroshima, Hiroshima, 일본
- Sadamori Ladies Clinic
-
-
Hokkaido
-
Sapporo, Hokkaido, 일본
- Kotoni Ladies Clinic
-
Sapporo, Hokkaido, 일본
- M's Ladies Clinic
-
Sapporo, Hokkaido, 일본
- Miyanomori Ladies' Clinic
-
Sapporo, Hokkaido, 일본
- Social Medical Corporation Caress Sapporo Caress Memorial Hospital
-
-
Hyōgo
-
Kako-gun, Hyōgo, 일본
- Kosumo Clinic
-
Nisinomiya-shi, Hyōgo, 일본
- Mari Women'S Clinic
-
-
Ibaraki
-
Toride, Ibaraki, 일본
- JA Toride Medical Center
-
Tsukuba, Ibaraki, 일본
- Tsukuba Urocare Clinic
-
-
Ishikawa-ken
-
Kanazawa, Ishikawa-ken, 일본
- National Hospital Organization Kanazawa Medical Center
-
-
Kagawa-ken
-
Takamatsu, Kagawa-ken, 일본
- Asahi Clinic
-
-
Kanagawa
-
Kamakura, Kanagawa, 일본
- Shonan Kamakura General Hospital
-
Kawasaki-shi, Kanagawa, 일본
- Kawasakieki Fumi Ladies Clinic
-
Kawasaki-shi, Kanagawa, 일본
- Koukan Clinic
-
Kawasaki-shi, Kanagawa, 일본
- Shinkawasaki Kobiki Womens Clinic
-
Yokohama, Kanagawa, 일본
- Motomachi Ladies Clinic
-
Yokohama, Kanagawa, 일본
- Women's Clinic LUNA Yokohama Motomachi
-
-
Kyoto
-
Kyoto, Kyoto, 일본
- Rakuwakai Otowa Hospital
-
-
Miyagi
-
Sendai, Miyagi, 일본
- Chieko Yukika Lady's Clinic
-
-
Nagano
-
Matsumoto-shi, Nagano, 일본
- Social Medical Care Corporation Hosei-kai Marunouchi Hospital
-
-
Oita Prefecture
-
Beppu-shi, Oita Prefecture, 일본
- National Hospital Organization Beppu Medical Center
-
-
Okayama-ken
-
Okayama, Okayama-ken, 일본
- Miyabi Uro-Gyne Clinic
-
-
Osaka
-
Kawachinagano-shi, Osaka, 일본
- National Hospital Organization Osaka Minami Medical Center
-
Osaka, Osaka, 일본
- Chayamachi Ladies Clinic
-
Osaka, Osaka, 일본
- Chiharu Clinic
-
Osaka, Osaka, 일본
- GyNet Medical Corporation Minamimorimachi Ladies' Clinic
-
Osaka, Osaka, 일본
- Kitahorie Kanade Ladies Clinic
-
Osaka, Osaka, 일본
- Komorebi Ladies Clinic Osaka Honmachi
-
Osaka, Osaka, 일본
- Ninomiya Ladies Clinic
-
Osaka, Osaka, 일본
- Rikako Ladies Clinic
-
Osaka, Osaka, 일본
- Tennoji Chihiro Women's Clinic
-
Sakai-shi, Osaka, 일본
- Shimizu Ladies Clinic
-
Takatsuki-shi, Osaka, 일본
- jMOG Medical Corporation Tanabe Ladies' Clinic
-
-
Saitama
-
Saitama, Saitama, 일본
- OHARA Clinic
-
Saitama-shi, Saitama, 일본
- Maruyama Memorial General Hospital
-
-
Shiga
-
Kusatsu-shi, Shiga, 일본
- Omi Medical Center, Social Medical Corporation Seikoukai
-
Ōmihachiman, Shiga, 일본
- Omihachiman Community Medical Center
-
-
Tokyo
-
Bunkyo-ku, Tokyo, 일본
- Sei Women's Clinic
-
Chiyoda-ku, Tokyo, 일본
- Marunouchi no Mori Ladies Clinic
-
Chuo-ku, Tokyo, 일본
- Medical Corporation Asbo Tokyo Asbo Clinic
-
Hachioji-shi, Tokyo, 일본
- Medical Corp. SEIKOUKAI New Medical Research System Clinic
-
Machida-shi, Tokyo, 일본
- Machida Municipal Hospital
-
Minato-ku, Tokyo, 일본
- Toranomon Womens Clinic
-
Musashino-shi, Tokyo, 일본
- Kichijyoji Ladies Clinic
-
Nerima-ku, Tokyo, 일본
- Shimamura Memorial Hospital
-
Nishi-Tokyo-shi, Tokyo, 일본
- Yukawa Women'S Clinic
-
Suginami-ku, Tokyo, 일본
- Shimodaira Ladies Clinic
-
Tama-Shi, Tokyo, 일본
- Medical Corporation Associa Tamacenter Ladies Clinic
-
-
Yamaguchi
-
Shunan-shi, Yamaguchi, 일본
- Japan Community Health care Organization Tokuyama Central Hospital
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
-
Participant confirmed as menopausal per one of the following criteria at the screening visit (visit 1):
- Spontaneous amenorrhea for >/=12 consecutive months;
- Spontaneous amenorrhea for >/=6 months with biochemical criteria of menopause (follicle-stimulating hormone (FSH) > 40 IU/L);
- Having had bilateral oophorectomy >/=6 weeks prior to the screening visit (visit 1) (with or without hysterectomy); or
- Having had hysterectomy without bilateral oophorectomy with the biochemical criteria of menopause (FSH > 40 IU/L).
-
Participant must be seeking treatment or relief for vasomotor symptoms (VMS) associated with menopause and meet some set criteria related to hot flash(es) (HFs) (VMS) prior to randomization.
-
Participant agrees not to participate in another interventional study while participating in the present study.
Exclusion Criteria:
- Participant has a history of an undiagnosed uterine bleeding within the 6 months prior to the screening visit (visit 1).
- Participant has a current malignant tumor or history (except for a participant who has not received treatment for malignant tumors for at least 5 years before informed consent acquisition and was not considered to have recurrence) of a malignant tumor except for non-metastatic basal cell carcinoma of the skin.
- Participant has a medical condition or chronic disease (including history of neurological [including cognitive], hepatic, renal, cardiovascular, gastrointestinal, pulmonary [e.g., moderate asthma], endocrine, or gynecological disease) that could confound interpretation of the study outcome.
- Participant uses a prohibited therapy (hormone therapy, hormone replacement therapy (HRT), hormonal contraceptive, any treatment for menopausal symptoms [prescription medications, over-the-counter, or herbal/Kampo medicines] or strong or moderate cytochrome P450 1A2 (CYP1A2) inhibitors) and is not willing to wash out or discontinue use of such drugs from screening visit (visit 1) through the follow-up visit (visit 6) or it is not medically appropriate to discontinue such drugs for the duration of the study.
- Participant has been randomized/registered in a clinical study with fezolinetant previously or had previous exposure to marketed fezolinetant elsewhere.
- Participant has a present or previous history of participation in this study.
- Participant has received any investigational therapy within 28 days or 5 half-lives, whichever is longer, prior to screening (visit 1).
- Participant has an unacceptable result from the transvaginal ultrasound (TVU) assessment at screening (i.e., full length of endometrial cavity cannot be visualized or presence of clinically significant abnormal findings).
- Participant has documentation of a clinically significant abnormal Papanicolaou (Pap) test (or equivalent cervical cytology) within the 12 months prior to the screening visit (visit 1) or at screening.
- Participant has active liver disease, jaundice, or elevated liver aminotransferases (alanine aminotransferase (ALT) or aspartate aminotransferase (AST)), elevated total bilirubin (TBL) or direct bilirubin (DBL), elevated international normalized ratio (INR), or elevated alkaline phosphatase (ALP) at screening. A participant with mildly elevated ALT or AST up to < 1.5 × upper limit of normal (ULN) can be enrolled if TBL and DBL are normal. Participant with mildly elevated ALP (up to < 1.5 × ULN) can be enrolled if cholestatic liver disease is excluded and no cause other than fatty liver is diagnosed. Participant with Gilbert's syndrome with elevated TBL may be enrolled as long as DBL, hemoglobin and reticulocytes are normal.
- Participant has creatinine > 1.5 × ULN or estimated glomerular filtration rate using the Modification of Diet in Renal Disease formula </=30 mL/min/1.73 m^2 at screening.
- Participant has positive hepatitis serology panel (i.e., positive hepatitis B surface (HBs) antigen and/or positive hepatitis C virus (HCV) antibody) at screening. If HCV antibody test result is equivocal, hepatitis C virus ribonucleic acid (HCV RNA) test at study site is allowed. Participant can be enrolled if that result is normal or not abnormal.
- Participant is not in good general health as determined on the basis of medical history and general physical examination performed at the screening; hematology parameters, biochemistry parameters, pulse rate, blood pressure, electrocardiogram (ECG) outside the reference range for the population studied, or is showing clinically relevant deviations.
- Participant has a history of suicide attempt or suicidal behavior within the 12 months prior to study enrollment or suicidal ideation within the 12 months prior to study enrollment (a response of "yes" to question 4 or 5 on the suicidal ideation portion of the Columbia Suicide Severity Rating Scale (C-SSRS)), or is at significant risk to commit suicide at day 1 (visit 2).
- Participant is unable or unwilling to complete the study procedures.
- Participant has any condition which makes the participant unsuitable for study participation.
- Participant has a known or suspected hypersensitivity to fezolinetant or any components of the formulation used.
- Participant is the investigator or a member of the study site staff.
- Participant is an employee of Astellas, the study-related contract research organizations (CROs) or site management organization.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 삼루타
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: Fezolinetant low dose
Participants will receive low dose of fezolinetant and placebo once daily for 12 weeks. |
oral
다른 이름들:
oral |
|
실험적: Fezolinetant high dose
Participants will receive high dose of fezolinetant and placebo once daily for 12 weeks. |
oral
다른 이름들:
oral |
|
위약 비교기: Placebo
Participants will receive matching placebo once daily for 12 weeks. |
oral |
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Mean change from baseline in the frequency of mild to severe vasomotor symptoms (VMS)
기간: Baseline and Week 8
|
Frequency of mild, moderate or severe VMS events will be calculated as the sum of mild, moderate or severe VMS events per day. |
Baseline and Week 8
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Mean change from baseline in the frequency of mild to severe VMS
기간: Baseline and up to Week 12
|
Frequency of mild, moderate or severe VMS events will be calculated as the sum of mild, moderate or severe VMS events per day. |
Baseline and up to Week 12
|
|
Mean change from baseline in the frequency of moderate to severe VMS
기간: Baseline and up to Week 12
|
Frequency of moderate or severe VMS events will be calculated as the sum of moderate or severe VMS events per day. |
Baseline and up to Week 12
|
|
Mean percent reduction in the frequency of mild to severe VMS from baseline
기간: Baseline and up to Week 12
|
Frequency of mild, moderate or severe VMS events will be calculated as the sum of mild, moderate or severe VMS events per day. Mean percent reduction will be reported. |
Baseline and up to Week 12
|
|
Mean percent reduction in the frequency of moderate to severe VMS from baseline
기간: Baseline and up to Week 12
|
Frequency of moderate and severe VMS events will be calculated as the sum of moderate or severe VMS events per day. Mean percent reduction will be reported. |
Baseline and up to Week 12
|
|
Percent reduction of >/= 50% in the frequency of mild to severe VMS from baseline
기간: Baseline and up to Week 12
|
Frequency of mild, moderate or severe VMS events will be calculated as the sum of mild, moderate or severe VMS events per day. Percent reduction of >/= 50% will be reported. |
Baseline and up to Week 12
|
|
Percent reduction of >/= 75% in the frequency of mild to severe VMS from baseline
기간: Baseline and up to Week 12
|
Frequency of mild, moderate or severe VMS events will be calculated as the sum of mild, moderate or severe VMS events per day. Percent reduction of >/= 75% will be reported. |
Baseline and up to Week 12
|
|
Percent reduction of 100% in the frequency of mild to severe VMS from baseline
기간: Baseline and up to Week 12
|
Frequency of mild, moderate or severe VMS events will be calculated as the sum of mild, moderate or severe VMS events per day. Percent reduction of 100% will be reported. |
Baseline and up to Week 12
|
|
Percent reduction of >/= 50% in the frequency of moderate to severe VMS from baseline
기간: Baseline and up to Week 12
|
Frequency of moderate and severe VMS events will be calculated as the sum of moderate or severe VMS events per day. Percent reduction of >/= 50% will be reported. |
Baseline and up to Week 12
|
|
Percent reduction of >/= 75% in the frequency of moderate to severe VMS from baseline
기간: Baseline and up to Week 12
|
Frequency of moderate and severe VMS events will be calculated as the sum of moderate or severe VMS events per day. Percent reduction of >/= 75% will be reported. |
Baseline and up to Week 12
|
|
Percent reduction of 100% in the frequency of moderate to severe VMS from baseline
기간: Baseline and up to Week 12
|
Frequency of moderate and severe VMS events will be calculated as the sum of moderate or severe VMS events per day. Percent reduction of 100% will be reported. |
Baseline and up to Week 12
|
|
Number of participants with Adverse Events (AEs)
기간: Up to Week 15
|
An AE is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study intervention. This includes events related to the comparator, if applicable, and events related to the (study) procedures. |
Up to Week 15
|
|
Change from baseline in endometrial thickness
기간: Baseline and up to Week 12
|
Endometrial thickness is a measure of how thick the lining of the uterus is. Endometrial thickness will be measured by transvaginal ultrasound (TVU). |
Baseline and up to Week 12
|
|
Number of participants with laboratory value abnormalities and/or AEs
기간: Up to Week 15
|
Number of participants with potentially clinically significant laboratory values. |
Up to Week 15
|
|
Number of participants with vital sign abnormalities and/or AEs
기간: Up to Week 15
|
Number of participants with potentially clinically significant vital sign values. |
Up to Week 15
|
|
Number of participants with electrocardiogram (ECG) abnormalities and/or AEs
기간: Up to Week 12
|
Number of participants with potentially clinically significant ECG values. |
Up to Week 12
|
|
Pharmacokinetics (PK) of fezolinetant in plasma: Concentration
기간: Up to Week 12
|
Concentration will be recorded from the PK plasma samples collected. |
Up to Week 12
|
|
Pharmacokinetics (PK) of metabolite ES259564 in plasma: Concentration
기간: Up to Week 12
|
Concentration will be recorded from the PK plasma samples collected. |
Up to Week 12
|
공동 작업자 및 조사자
수사관
- 연구 책임자: Associate Medical Director, Astellas Pharma Inc
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (실제)
연구 완료 (실제)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
- 2693-CL-0310
- jRCT2031230571 (레지스트리 식별자: jRCT)
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
IPD 계획 설명
Access to anonymized individual participant level data collected during the study, in addition to study-related supporting documentation, is planned for studies conducted with approved product indications and formulations, as well as products terminated during development. Studies conducted with product indications or formulations that remain active in development are assessed after study completion to determine if Individual Participant Data can be shared. Further details on Astellas' data sharing policy can be found at https://www.clinicaltrials.astellas.com/transparency/.
IPD 공유 기간
Access to participant level data is offered to researchers after publication of the primary manuscript (if applicable) and is available as long as Astellas has legal authority to provide the data.
IPD 공유 액세스 기준
Researchers must submit a proposal to conduct a scientifically relevant analysis of the study data. The research proposal is reviewed by an Independent Research Panel. If the proposal is approved, access to the study data is provided in a secure data sharing environment after receipt of a signed Data Sharing Agreement.
IPD 공유 지원 정보 유형
- 연구_프로토콜
- 수액
- CSR
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .